The conclusions of later cohort studies or meta-analyses were inconsistent, reporting either no excess risk or an elevated pancreatic cancer risk associated with GLP-1R therapies (49–51); however, the risk may be influenced by the severity of T2D (50). This evidence concerns the gene GLP1R and familial pancreatic carcinoma.